Abbott Laboratories (ABT)
| Market Cap | 217.50B |
| Revenue (ttm) | 43.84B |
| Net Income (ttm) | 13.93B |
| Shares Out | 1.74B |
| EPS (ttm) | 7.96 |
| PE Ratio | 15.71 |
| Forward PE | 22.60 |
| Dividend | $2.36 (1.89%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 4,360,770 |
| Open | 125.66 |
| Previous Close | 125.40 |
| Day's Range | 124.64 - 126.05 |
| 52-Week Range | 110.86 - 141.23 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 146.61 (+17.21%) |
| Earnings Date | Jan 21, 2026 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $146.61, which is an increase of 17.21% from the latest price.
News
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
Aging, nutrition and lifestyle affect muscles, especially after age 40. That's why Matt Ryan, former professional quarterback and MVP, is teaming up with Abbott to drive muscle health awareness with t...
This Top Dividend King Just Became an Even Better Buy
Abbott Laboratories is acquiring Exact Sciences, in a move that will help bolster its diagnostics business. Abbott should expand the reach of Exact Sciences' key products and fuel its innovative engin...
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
Abbott issues US device correction for some glucose monitors over faulty readings risk
Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some...
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact...
Top 2 Healthcare Stocks Every New Investor Should Know
These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding.
2 Fantastic Dividend Stocks to Buy and Hold Forever
Abbott and Medtronic are innovative healthcare leaders that generate consistent revenue and profits. They also have attractive long-term prospects and have consistently raised their dividend payouts.
Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics
Abbott Laboratories (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ: EXAS) for $105 per common share, representing a total equity value of approximately ...
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Abbott to Acquire Exact Sciences for $21 Billion
Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.
Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences
Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business.
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics...
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.
2 Sweet Dividend Stocks to Buy to Satisfy Your Craving for Passive Income
These companies are leaders in their industries and well-positioned to deliver steady growth over time. They also offer dividend yields higher than that of the S&P 500.
Invesco Diversified Dividend Fund Q3 2025 Portfolio Positioning
Dupont (DD) is a leading specialty chemical company in the process of spinning off its electronics business, which in our view should unlock shareholder value. KKR (KKR) is a leading private equity in...
2 Top Dividend Stocks to Buy and Hold Forever
Dividend stocks can help meet the needs of a variety of investors. The two dividend stocks below are among the leaders in their industries.
10 Defensive Stocks with Market-Beating Yields
It's been a great year for stocks, but in the past few days the bull market seems to have lost some of its mojo.
Best Dividend Aristocrats For November 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW...
Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV
Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media Boston Teacher Shares Life-Changing Ex...
Best Dividend Kings: October 2025
Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Top performers include NFG, JNJ, ABBV, MO, FTS, ADM, NUE, GRC, NWN, PH...
Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports
Walmart will become the first U.S. retailer to sell an over-the-counter continuous glucose monitor in physical stores, as Abbott Laboratories' Lingo rolls out to more than 3,500 locations and online, ...
Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming
The market has overreacted to ABT's lowered FY2025 organic sales growth/narrowed adj. EPS, since the management continues to deliver robust numbers while building upon FY2024 outperformance. Much of i...
These Analysts Revise Their Forecasts On Abbott Following Q3 Results
Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.